ClinicalTrials.gg
RecruitingNCT04798690Updated Jul 21, 2026

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

An observational study in Growth Hormone Deficiency, Idiopathic Short Stature and Turner Syndrome, sponsored by Dong-A ST Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Dong-A ST Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
5,000
Ages
2 Years and older
Sex
All
01

Study summary

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.

02

Conditions studied

  • Growth Hormone Deficiency
  • Idiopathic Short Stature
  • Turner Syndrome
  • Small for Gestational Age
03

In context

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 70 across 73 observational studies indexed under Dwarfism, Pituitary.

Browse Dwarfism, Pituitary studies →

Lead sponsor

Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Short stature by GHD or ISS or TS or SGA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
  • Children who has official height record at least 6 months prior

Exclusion criteria

Exclusion Criteria:

  • Children with Epiphyseal closure
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
5,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Growth hormone

    Growtropin®-II

06

What researchers measure

Primary outcomes

  1. Long term safety assessed through the adverse events

    Number of occurrence of treatment-related adverse events

    Time frame: Up to 2 years after epiphyseal closure

Secondary outcomes

  1. Change of annualized height velocity

    To assess the difference in change of annualized height velocity between baseline and every 6 months

    Time frame: Up to 2 years after epiphyseal closure

  2. The difference between target height and final height

    To assess the difference in target height and final height

    Time frame: Up to 2 years after epiphyseal closure

  3. Changes in Height SDS

    To assess the changes in Height SDS between baseline and every 6 months

    Time frame: Up to 2 years after epiphyseal closure

  4. Changes in skeletal maturity

    To assess the changes in skeletal maturity between baseline and every 6 months

    Time frame: Up to 2 years after epiphyseal closure

  5. Changes in IGF-1

    To assess the changes in IGF-1 between baseline and every 6 months

    Time frame: Up to 2 years after epiphyseal closure

  6. Changes in IGFBP-3

    To assess the changes in IGFBP-3 between baseline and every 6 months

    Time frame: Up to 2 years after epiphyseal closure

  7. Changes in BMI SDS

    To assess the changes in BMI SDS between baseline and every 6 months

    Time frame: Up to 2 years after epiphyseal closure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2035, 168 months after the start.

Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's planned 168 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2021
First posted
Mar 15, 2021
StartActual
Feb 8, 2021
Primary completionEst.
Feb 2035
CompletionEst.
Feb 2035
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04798690
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Feb 8, 2021
Primary completion
Feb 2035 (estimated)
Completion
Feb 2035 (estimated)
Last update
Jul 21, 2026

Study contacts

Sung
Contact
jhsung@donga.co.kr
+82-2-920-8369

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion